Relief Therapeutics Holding AG
MindMaze Therapeutics Holding SA develops and operates the MindMaze platform that integrates neuroscience and digital therapeutics to address some of the most pressing challenges in neurology. MindMaze Therapeutics Holding SA was formerly known as NeuroX Group SA. The company was incorporated in 2025 and is based in Lausanne, Switzerland.
Relief Therapeutics Holding AG - Asset Resilience Ratio
Relief Therapeutics Holding AG (RLFTY) has an Asset Resilience Ratio of 1.23% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2021)
This chart shows how Relief Therapeutics Holding AG's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Relief Therapeutics Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.22 Million | 1.23% |
| Total Liquid Assets | $2.22 Million | 1.23% |
Asset Resilience Insights
- Limited Liquidity: Relief Therapeutics Holding AG maintains only 1.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Relief Therapeutics Holding AG Industry Peers by Asset Resilience Ratio
Compare Relief Therapeutics Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Relief Therapeutics Holding AG (2020–2021)
The table below shows the annual Asset Resilience Ratio data for Relief Therapeutics Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $251.62 Million | -- |
| 2020-12-31 | 0.24% | $185.00K | $78.05 Million | -- |